TABLE 3.

Neutralizing activity of anti-gp120 RhMAbs by competition group

MAb competition group (binding site)Concn of MAb (μg/ml) reducing infectivity by 50%a
SIV239g46g56M5SIV251labSIV316ΔV1V2
I (NH2)
    H312.10.10.3
    3.8E
    3.10C
II (V1 loop)
    3.10A0.1
III (V2 loop)
    5.5B0.04
IV (V3 loop)
    3.11G3.50.60.4
    3.11H0.20.0050.08
V
    1.1C>5.30.020.0034.0
    1.11A0.090.012.5
    3.4E0.0020.04
VIa
    3.11E6.33.50.050.00090.001
VI
    1.9C6.40.50.0010.003
    3.5B0.040.0020.0005
    3.5F0.00010.004
    3.7C0.060.0030.003
    E310.00020.05
VII (V4)
    3H310.00.0030.002
    C266.00.00080.0002
    1.10A10.0>15.615.03.80.0040.0003
VIII (?)
    3B3
  • a The numbers indicate the concentration of MAb required to reduce infectivity of the indicated virus by 50%. −, neutralization was not detected. >, neutralization was observed, but 50% neutralization was not achieved at the highest concentration tested (typically 10 μg/ml or higher).